Pharma channel feed – Endpoints News

Pharma channel feed

Pfizer racks up its third cancer drug OK in 2 months, but is it enough to replace regular price hikes?

7 years ago

Trevena hammered again as the FDA spurns their controversial pain drug — but AcelRx gets a green light

7 years ago

J&J dumps PhII-ready CD28 autoimmune asset, returns rights to French partner

7 years ago

Illumina forks out $1.2B to buy rival Pacific Biosciences, placing long and short-read DNA tech under the same roof

7 years ago

FDA experts gun down Alkermes’ pitch for ALKS-5461, slamming the company on multiple fronts

7 years ago

FDA preps for a new and flexible approach to genome editing in animals

7 years ago

GW's cannabis-derived drug Epidiolex finally launches in the US with an average list price of $32,500

7 years ago

6 months after arriving at Sanofi R&D, John Reed gambles $125M on Denali’s RIPK1 work

7 years ago

FDA staff suggests safety profile of Sage postpartum depression drug disqualifies it from at-home infusions

7 years ago

Weeks after launching Aeterna Zentaris castoff, Strongbridge turns around and sells rights to Novo Nordisk — at a premium

7 years ago

Arch Venture sets its sights on raising $600M for Fund X

7 years ago

Problems, problems, problems: But Alkermes will fight it out this week over the FDA’s objections to its big depression drug ALKS 5461

7 years ago

AstraZeneca hands over some rights to Nexium, Vimovo to Grünenthal as it plots turnaround

7 years ago

TherapeuticsMD wins FDA nod for hormone therapy, capping off drugmaker's prolific year

7 years ago

Pfizer, Novartis tie up to target NASH in crowded field

7 years ago

On a roll, Dicerna notches $100M upfront as Eli Lilly eyes RNAi applications in neurodegeneration, pain

7 years ago

Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout

7 years ago

Constipation drug maker Synergy looks to renegotiate bloated loan agreement — shares tumble

7 years ago

FDA kicks Regeneron’s latest Eylea application to the curb, but they’re not sweating it

7 years ago

As talk of drug pricing takes center stage, Amgen slashes Repatha price by nearly 60%

7 years ago

Trump to unveil proposal to reduce prices on doctor-administered drugs as midterms loom

7 years ago

Roche's new, single-dose flu drug gets the green light at a hard charging FDA, breaking into record-setting territory

7 years ago

AbbVie is going for it in cystic fibrosis. But why are they buying the weak Galapagos portfolio in a $245M deal?

7 years ago

Alexion doles out $22M upfront for two preclinical RNAi drugs from Dicerna

7 years ago

First page Previous page 284 285 286287288 289 290 Next page Last page